Covid Vaccine Race

Trying to increase COVID-19 vaccination rates in these populations has been challenging. In an attempt to do so, a randomized clinical trial across 133 skilled nursing facilities (SNFs) was performed.

Intranasal COVID-19 vaccines aren’t just needle and pain-free—they may also be more effective at protecting against current and future variants.

A recent study in Guangdong, China, confirmed vaccine effectiveness of inactivated COVID-19 vaccines against the Delta variant of COVID-19.

Not all people unvaccinated against COVID-19 people are actively avoiding the vaccine. A new study shows that Black people were vaccinated at lower rates than White people in the US early on, even after they indicated they were willing to get the shot. The study’s authors explain the reasons behind this.

The company recently submitted its data to the federal regulatory authorities for an Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. As it's time to think about this potential vaccine being available in the US, clinicians offer some insights and perspective on it.

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted 13-0 in favor of the vaccine for adults.

Pfizer-BioNTech asked the FDA for Emergency Use Authorization to administer its COVID-19 vaccine to children 6 months-5 years of age, despite evidence that 2 vaccine doses may not be enough to elicit the desired immune response.

The company’s filing for its NVX-CoV2373 vaccine is based off data from 2 large clinical trials.

Health care workers in Taiwan who were previously infected with SARS-CoV-1 showed a more robust antibody response to the AstraZeneca COVID-19 vaccine, a new study found.

Backed by solid data, clinicians can work to overcome vaccine hesitancy due to fears about negative pregnancy outcomes.

Moderna recipients were less likely to experience COVID-19 breakthrough infections and hospitalizations than the Pfizer-BioNTech group.

A booster vaccination increases protection against COVID-19 whether homologous or heterologous with the primary vaccine.

The Centers for Disease Control and Prevention (CDC) compared 2-dose mRNA vaccination to third dose booster and to unvaccinated, against both Omicron and Delta variants of SARS-CoV-2.

Company announced it had administered its first shot to a participant for its extension of an earlier phase 2 study.

The companies said the vaccines will be examined in adults 18-55 years old.

Booster doses of the Pfizer-BioNTech COVID-19 vaccine were shown to provide greater protection against infection than the 2 dose primary regimen alone, according to a study of health care workers in Israel.

A third dose of the Pfizer-BioNTech or AstraZeneca mRNA COVID-19 vaccines produced sufficient neutralizing antibody titers against the Omicron variant.

Former members of the Biden transition team recommend accepting that the virus is here to stay.

As global health leaders discuss the best long-term strategy for COVID-19 vaccines and boosters, consensus is emerging that repeated boosters of current vaccines within short intervals is not sustainable.

During a continuation of a difficult time in our history, overwhelmed providers need to take a step back and find time for themselves to unwind and destress from COVID-19.

Pfizer CEO Albert Bourla made the announcement in an interview.

New data suggests an additional “booster” dose of an mRNA COVID-19 vaccine is no longer just recommended but required for protection against the infectious Omicron variant.

Vaccine hesitancy is a significant hurdle experienced in the US. In response to this, a team of researchers analyzed adults who reported a medical provider recommended the COVID-19 vaccine, studied vaccination status, and general attitudes.

After increased awareness soon after the emergence of COVID-19, fewer Americans see plight of people of color.

The Advisory Committee on Immunization Practices (ACIP) voted yes to a third shot of the Pfizer-BioNTech COVID-19 vaccine in this pediatric population.

Novavax’s COVID-19 vaccine demonstrated 90.4% efficacy in a phase 3 trial with no moderate or severe cases reported among participants in the treatment group.

The FDA now recommends Americans 12 years and older receive COVID-19 booster shots. Additionally, they moved to shorten the time in between the second and third dose from 6 months to 5 for Pfizer-BioNTech recipients.

Investigators in the United Kingdom showed a Pfizer-BioNTech booster dose increases neutralizing antibodies in a laboratory setting, and Omicron might not be as damaging to the lungs as previous variants.

The fast-moving Omicron variant demonstrates a high transmissibility, but not as significant a hospitalization rate or mortality.

The US is on track to reach new records for 7-day average cases, though death rates remain lower.